The HeadquartersCorporate ProfileThe OrganisationFIVB Story
Volleyball StoryChronological HighlightsBeach Volleyball OriginsRulesFundamentals
CompetitionsCalendarWorld RankingsOfficial RulesOfficial FormsVolleyball Story
CompetitionsPlayer BiosWorld RankingsRulesFormsBeach Volleyball OriginsRefereeing
Volleyball Cooperation Programme (VCP)Development CentresTechnical e-libraryTechnical Video EvaluationU-VolleyInternational CooperationMini/School VolleyballPark Volley
Contact l RSS RSS Facebook Twitter YouTube l Login
NEWS

Anti-doping - FIVB closes Salgado case

 
FIVB President Jizhong Wei said: "The FIVB is fully committed to the fight against doping and devotes significant resources annually for doping controls and anti-doping education."
 

Lausanne, Switzerland, October 25, 2011 – The International Volleyball Federation (FIVB) has decided, following weeks of extensive research due to concern surrounding the initial results from the WADA-accredited laboratory in Rio de Janeiro, that it will close the doping case concerning the Brazilian men’s beach volleyball player Pedro Solberg Salgado announcing that new evidence received from the WADA-accredited laboratory in Cologne clears him of any suspicion.

Following an out of competition test on May 30, WADA informed the FIVB on July 8 that the sample analysis showed the presence of the prohibited substance 5α-androstane-3α,17β-diol and that the results of the analysis were consistent with exogenous administration, at which point Salgado was provisionally suspended. Due to delays with the analysis of the B sample in the Rio laboratory, Salgado’s temporary suspension was lifted one month later.

On August 12, the Rio Laboratory informed the FIVB that the analysis of the B sample confirmed the adverse analytical finding. However, a detailed review of the laboratory documentation packages by the FIVB revealed some analytical issues which still needed to be addressed. Therefore, on September 23 the FIVB requested the WADA-accredited laboratory in Cologne to perform additional analyses on the athlete’s sample.

The Cologne Laboratory informed the FIVB on October 21 that their extended analyses for testosterone and testosterone metabolites did not indicate an application of testosterone or testosterone prohormones. None of the target compounds indicated an exogenous origin.

Having considered the circumstances of the case and in particular the compelling scientific evidence submitted recently before it, the FIVB concluded that there is no evidence of an anti-doping rule violation that could justify the assignment of the case to the FIVB Doping Hearing Panel.

“As a signatory to the World Anti-Doping Code, the FIVB is fully committed to the fight against doping and devotes significant resources annually for doping controls and anti-doping education,” FIVB President Jizhong Wei said. “In this important battle, however, we cannot afford losing confidence in the analytical results of WADA-accredited laboratories.

“As much as we need to identify and sanction those who cheat, we must ensure that no athlete is faced with a false positive. For this reason I am satisfied that, after review of the complete laboratory documentation, FIVB followed the recommendations of its own experts and decided to ask for an additional analysis prior to sanctioning the athlete.”

“The FIVB will now ask WADA to investigate the cause for the contradictory analytical findings. We trust that WADA will carefully look into this regrettable incident and will succeed in further harmonizing the analytical procedures used by the laboratories,” FIVB Medical Commission president Dr. Roald Bahr added.





 Language(s)
   English

 Additional links
   Download high-resolution photo
   Medical home page

LATEST NEWS

Latest headlines